These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8480475)

  • 41. Effect of weight loss on glucose disposal in obese and obese diabetic patients.
    Golay A; Felber JP; Dusmet M; Gomez F; Curchod B; Jéquier E
    Int J Obes; 1985; 9(3):181-91. PubMed ID: 3902687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients.
    Bianchi R; Bongers V; Bravenboer B; Erkelens DW
    Diabetes Care; 1993 Apr; 16(4):557-9. PubMed ID: 8462377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stimulation of human whole-body energy expenditure by salsalate is fueled by higher lipid oxidation under fasting conditions and by higher oxidative glucose disposal under insulin-stimulated conditions.
    Meex RC; Phielix E; Moonen-Kornips E; Schrauwen P; Hesselink MK
    J Clin Endocrinol Metab; 2011 May; 96(5):1415-23. PubMed ID: 21289240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of hepatic insulin action in obese type 2 diabetic patients.
    Staehr P; Hother-Nielsen O; Levin K; Holst JJ; Beck-Nielsen H
    Diabetes; 2001 Jun; 50(6):1363-70. PubMed ID: 11375337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Diazoxide-Mediated Insulin Suppression on Glucose and Lipid Metabolism in Nondiabetic Obese Men.
    Loves S; van Groningen L; Filius M; Mekking M; Brandon T; Tack CJ; Hermus A; de Boer H
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2346-2353. PubMed ID: 29618011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.
    Bramnert M; Segerlantz M; Laurila E; Daugaard JR; Manhem P; Groop L
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1455-63. PubMed ID: 12679422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
    Christopher M; Hew FL; Oakley M; Rantzau C; Alford F
    J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
    Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lack of effect of a physiological elevation of plasma non-esterified fatty acid levels on insulin secretion.
    Frias JP; Basabe L; Macaraeg G; Kruszynska YT
    Diabetes Metab; 2000 Apr; 26(2):133-9. PubMed ID: 10804328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different effects of IGF-I on insulin-stimulated glucose uptake in adipose tissue and skeletal muscle.
    Frick F; Oscarsson J; Vikman-Adolfsson K; Ottosson M; Yoshida N; Edén S
    Am J Physiol Endocrinol Metab; 2000 Apr; 278(4):E729-37. PubMed ID: 10751208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of dexfenfluramine on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals.
    Holdaway IM; Wallace E; Westbrooke L; Gamble G
    Int J Obes Relat Metab Disord; 1995 Oct; 19(10):749-51. PubMed ID: 8589769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fat oxidation, body composition and insulin sensitivity in diabetic and normoglycaemic obese adults 5 years after weight loss.
    Poynten AM; Markovic TP; Maclean EL; Furler SM; Freund J; Chisholm DJ; Campbell LV
    Int J Obes Relat Metab Disord; 2003 Oct; 27(10):1212-8. PubMed ID: 14513069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM.
    Marks SJ; Moore NR; Clark ML; Strauss BJ; Hockaday TD
    Obes Res; 1996 Jan; 4(1):1-7. PubMed ID: 8787932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of a novel beta-adrenoceptor agonist (Ro 40-2148) on resting energy expenditure in obese women.
    Haesler E; Golay A; Güzelhan C; Schutz Y; Hartmann D; Jéquier E; Felber JP
    Int J Obes Relat Metab Disord; 1994 May; 18(5):313-22. PubMed ID: 7914795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of prior high-intensity exercise on glucose metabolism in normal and insulin-resistant men.
    Devlin JT; Horton ES
    Diabetes; 1985 Oct; 34(10):973-9. PubMed ID: 3930321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study.
    Donjacour CE; Aziz NA; Overeem S; Kalsbeek A; Pijl H; Lammers GJ
    Sleep; 2014 Apr; 37(4):795-801. PubMed ID: 24899766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
    Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
    Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes.
    Simpson HL; Jackson NC; Shojaee-Moradie F; Jones RH; Russell-Jones DL; Sönksen PH; Dunger DB; Umpleby AM
    J Clin Endocrinol Metab; 2004 Jan; 89(1):425-32. PubMed ID: 14715881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Turnover and oxidation rates of plasma-free fatty acids in obese patients treated with dexfenfluramine.
    Greco AV; Mingrone G; Tataranni PA; Raguso C; De Gaetano A; Tacchino RM; Lavielle R; Ghirlanda G
    Ann Nutr Metab; 1993; 37(5):237-44. PubMed ID: 8311417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contribution of obesity to insulin resistance in noninsulin-dependent diabetes mellitus.
    Perriello G; Misericordia P; Volpi E; Pampanelli S; Santeusanio F; Brunetti P; Bolli GB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2464-9. PubMed ID: 7629243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.